Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882922 | 0.84 | ALDH1A1 (0.58) | HSD17B10PKMMAPTMEN1KMT2A | |
| SCHEMBL9447444 | 0.81 | PKM (0.61) | HSD17B10PDE10APKMMAPTPOLB | |
| SCHEMBL17391050 | 0.78 | HSD17B10 (0.56) | HSD17B10PDE10APKMMAPTPOLB | |
| SCHEMBL30320202 | 0.78 | HSD17B10 (0.56) | HSD17B10PDE10APKMMAPTPOLB | |
| SCHEMBL29451720 | 0.76 | PKM (0.70) | HSD17B10PDE10APKMMAPTPOLB | |
| SCHEMBL4604023 | 0.76 | PKM (0.70) | HSD17B10PDE10APKMMAPTPOLB | |
| SCHEMBL3281437 | 0.76 | HSD17B10 (1.00) | HSD17B10PKMMAPTPOLBMEN1 | |
| Hydrochloric Acid SCHEMBL9381859 | 0.75 | PKM (0.68) | HSD17B10PDE10APKMMAPTPOLB | |
| Bromide SCHEMBL7435506 | 0.75 | PKM (0.68) | HSD17B10PDE10APKMMAPTPOLB | |
| SCHEMBL5612552 | 0.74 | MAPT (0.56) | HSD17B10PKMMAPTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1309589-B1 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1619184-A2 | Urea compounds as kinase inhibitors | Amgen, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HSD17B10 2087/4885PDE10A 1420/4885PKM 580/4885 |
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | HSD17B10 2478/4885PDE10A 1229/4885PKM 1064/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HSD17B10 2087/4885PDE10A 1420/4885PKM 580/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HSD17B10 2087/4885PDE10A 1420/4885PKM 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.